Loading…
Akari Therapeutics Plc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in AKTX.
▼ -99.3% over 5Y.
today you would have $7.48▼ -99.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $11.56 | $48.80 | $124.80 | $376.00 | |
| P/B | 116762.9x | 36946.0x | 116762.9x | — | 1562975.3x |
| EPS | $0.00 | $0.00 | $0.00 | -$216.00 | |
| ROE | -89.03% | -61.06% | -89.03% | — | -990.95% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CCMConcord Medical Services Holdings Ltd | $4.76 | — | — | — | -21.88% | $20.67M |
| CTSOCytosorbents Corp | $0.34 | — | — | — | -336.21% | $21.09M |
| LFWDLifeward Ltd. | $7.46 | — | 3.3x | — | -225.65% | $21.13M |
| COCPCocrystal Pharma, Inc. | $1.10 |
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Company description provided by Yahoo Finance.
| — |
| 14.5x |
| — |
| -311.68% |
| $21.19M |
| NEUPNeuphoria Therapeutics Inc. | $3.76 | — | 0.7x | — | -62.90% | $20.32M |
| LGVNLongeveron Inc. | $6.72 | — | 20.5x | — | -203.61% | $21.42M |